Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

4.

Ineffective medication can remove the "worst fear" of schizophrenia.

5.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot